A fully-loaded product pipeline in various stages of clinical development, Nobel Prize-winning advisors, partnerships with the University of Oxford and Yale University — and much more. At the heart of each one of our initiatives is a commitment to rigorous scientific research.

Product Pipeline

Our current pipeline includes preclinical and clinical trials for skin, microbiome, muscle, cognition, UV damage, menopausal syndromes, and circadian rhythm. Beyond Basis, Matter, and Index, we are working with our scientific advisors and university partners to identify promising new research and innovative compounds.

These compounds are all tested for safety and efficacy in placebo-controlled human trials before coming to market.

As you can see from our preclinical studies and clinical trials outlined below, there’s a lot happening behind the scenes at Elysium — and a lot to look forward to.

Clinical Trials

Clinical research is incredibly important to us. We study our products in humans so you can be confident that your decisions are based on scientific evidence.

Non-Alcoholic Fatty Liver (NAFL)

Completed human clinical trial to study the effects of Basis on liver fat accumulation in healthy adults with fatty liver; results will be announced in 2022 and published by 2023.

Acute Kidney Injury (AKI) Phase I

Published in BMC Nephrology, the Phase I human clinical trial, conducted in partnership with Massachusetts General Hospital, enabled the FDA approval of an Investigational New Drug application for Basis and the AKI Phase II trial.

Acute Kidney Injury (AKI) Phase II

Initiated at Mayo Clinic, the human clinical trial will evaluate the efficacy of Basis for the prevention of AKI in patients that have undergone a cardiac surgery; primary study completion date October 2023.

Repeat Dose Basis

Elysium’s first human clinical trial showed that a daily dose of Basis is a safe and effective way to sustainably increase NAD+ levels by an average of 40% from baseline.

NR-E Toxicology Study

Completed and published in the International Journal of Toxicology. The results showed that Elysium’s proprietary nicotinamide riboside (NR-E) has a superior safety profile to all other consumer NR products.

NAD+ Baseline

Initiated in collaboration with Duke Clinical Research Institute, this clinical trial will evaluate correlations between epigenetic aging (measured using Index) and NAD+ levels in healthy adults; expected completion 2022/2023.

UV Damage

Completed study to assess the effects of nicotinamide riboside (NR) and pterostilbene (PT) on UV-induced swelling, immunosuppression, and markers of DNA damage in mice; study will be published in 2022 or 2023.

Menopausal Syndromes

Working in partnership with the University of South Alabama, this pilot study will evaluate the effects of Basis supplementation on menopausal syndromes. Expected completion date 2022.

EH301 for ALS

Working in collaboration with the Spanish Foundation for ALS Research (FUNDELA), the results of this pilot study showed evidence the experimental therapeutic EH301 can be used in treatment of amyotrophic lateral sclerosis (ALS).

NO-ALS (EH301)

Initiated with partners at Haukeland University Hospital, this human clinical trial will evaluate the efficacy of the experimental therapeutic EH301 for the treatment of amyotrophic lateral sclerosis (ALS); expected completion date December 2022.


Initiated with partners at the University of Copenhagen and funded by a grant from the Danish Government, this clinical trial will evaluate the effect of Elysium’s proprietary nicotinamide riboside (NR-E) on clinical outcomes in elderly patients with COPD. Expected completion date is late 2022.

Academic Partnerships

We’ve established multi-year research partnerships with leading institutions, including Harvard and Oxford, to break new ground in aging research.
Oxford University - Elysium Health

Oxford University

Matter, our breakthrough product clinically proven to slow age-related brain atrophy, was developed in partnership with the University of Oxford and world-renowned scientist A. David Smith, Ph.D., Professor Emeritus of Pharmacology at the University of Oxford, Founding Director of OPTIMA, and Elysium Scientific Advisory Board member.

The Oxford-Elysium Fellowship Program - Elysium Health

The Oxford-Elysium Fellowship Program

Elysium has established the Oxford-Elysium Fellowship program at the University of Oxford, which recruits the best researchers to work in cutting-edge laboratories. 

The first fellow, Hanlin Zhang, discovered a new pathway for autophagy induction. Zhang works in the lab of Katja Simon, Professor of Immunology in the Kennedy Institute of Rheumatology in the Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences. Elysium owns first rights to all intellectual property developed by the fellow.

The second fellow, Adam Rolt, works in the lab of Lynne Cox at the University of Oxford’s Cox Lab of Ageing and Cell Senescence. Cox’s lab focuses on the genes and biochemical pathways that influence health outcomes in aging and promote healthy aging by treating age-related diseases at the cause.

Lewis Taylor is the third fellow in the Oxford-Elysium program, and works in Aarti Jagannath’s lab at the Nuffield Department of Clinical Neuroscience. Taylor’s focus is on researching the relationship between circadian rhythms, chronic disease, and biological age.

For further details on the Oxford-Elysium program and how to apply for fellowship, read more.

Partnership With Yale University - Elysium Health

Partnership With Yale University

Elysium partnered with Yale University to develop Index, our revolutionary at-home epigenetic test spearheaded by Elysium’s Bioinformatics Advisor Morgan Levine, Ph.D. Levine is a ladder-rank assistant professor in the Department of Pathology at the Yale School of Medicine and a member of both the Yale Combined Program in Computational Biology and Bioinformatics, and the Yale Center for Research on Aging.

Elysium Scholars: Helping Students Study Science - Elysium Health

Elysium Scholars: Helping Students Study Science

Elysium’s scholarship program is designed to encourage and assist students pursuing an education in science-related fields. There are currently six students enrolled in an undergraduate degree in a scientific field benefiting from the scholarship.

“Through Elysium Health's products and research focus on human health, the Elysium Scholars program takes an expansive approach to science. We believe that encouraging young people to pursue a career in any scientific field is a critical step toward future breakthroughs and innovations that may have a meaningful impact on the overall health of our society." - Elysium co-founder and chief scientist Leonard Guarente, Ph.D.

Elysium Scholars is not currently accepting new applicants.